ArticleJACC. Basic to translational science2020
Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits.
Article in JACC. Basic to translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Prevention of in-stent restenosis with drug-eluting balloons in patients with postirradiated carotid stenosis accepting percutaneous angioplasty and stenting.Journal of neurointerventional surgery · 2023Trial
- Serial Optical Coherence Tomography Assessment of Plaque Phenotype Stabilization after Paclitaxel-Coated Balloon Treatment in De Novo Coronary Lesions.Yonsei medical journal · 2026Article
- High-Speed Intravascular Near-Infrared Fluorescence-Ultrasound Imaging In Vivo.IEEE transactions on bio-medical engineering · 2026Article
- DCB therapy: quo vadis?Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Applications and challenges of paclitaxel- coated balloons beyond coronary atherosclerotic heart disease.World journal of clinical cases · 2025Review
- Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention Association of Thailand.Journal of clinical medicine · 2025Review
- Intravascular Imaging and Pathological Features of Drug-Coated Balloon Angioplasty in Atherosclerotic Porcine Peripheral Arteries.Journal of atherosclerosis and thrombosis · 2025Article
- Advances in drug-coated balloons for the treatment of coronary artery de novo large-vessel lesions.The Journal of international medical research · 2025Review
- Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease.Scientific reports · 2025Article
- Targeted drug delivery systems for atherosclerosis.Journal of nanobiotechnology · 2025Review
- Emerging Hybrid Intracoronary Imaging Technologies and Their Applications in Clinical Practice and Research.JACC. Cardiovascular interventions · 2024Review
- Paclitaxel-coated balloons for vulnerable lipid-rich plaques.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Article
- Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design.BMC cardiovascular disorders · 2024Article
- Novel Payloads to Mitigate Maladaptive Inward Arterial Remodeling in Drug-Coated Balloon Therapy.Journal of biomechanical engineering · 2023Article
- First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study.Journal of clinical medicine · 2023Article
- Intracoronary Imaging of Coronary Atherosclerotic Plaque: From Assessment of Pathophysiological Mechanisms to Therapeutic Implication.International journal of molecular sciences · 2023Review
- Stent, balloon and hybrid inThe British journal of cardiology · 2023Article
- Understudied factors in drug-coated balloon design and evaluation: A biophysical perspective.Bioengineering & translational medicine · 2023Review
- Plaque characteristics after endovascular treatment in patients with intracranial atherosclerotic disease.Chinese neurosurgical journal · 2022Article
- Response to pre-dilatation with POBA can predict target lesion revascularization after DCB angioplasty for de novo small coronary artery lesions.The Journal of international medical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
Abstract
Paclitaxel drug-coated balloons (DCBs) reduce restenosis, but their overall safety has recently raised concerns. This study hypothesized that DCBs could lessen inflammation and reduce plaque progression. Using 25 rabbits with cholesterol feeding- and balloon injury-induced lesions, DCB-percutaneous transluminal angioplasty (PTA), plain PTA, or sham-PTA (balloon insertion without inflation) was investigated using serial intravascular near-infrared fluorescence-optical coherence tomography and serial intravascular ultrasound. In these experiments, DCB-PTA reduced inflammation and plaque burden in nonobstructive lesions compared with PTA or sham-PTA. These findings indicated the potential for DCBs to serve safely as regional anti-atherosclerosis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.